EGFR and non-small cell lung carcinoma: Consistent with this model, pharmacological inhibition of YAP/TEAD can deplete the reservoir of persister cells, resulting in an enhanced NSCLC response to EGFR/MEK [11] and anaplastic lymphoma kinase (ALK) [48] inhibitors.